ORIC PHARMACEUTICALS, INC. Class of Warrant or Right, Outstanding
ORIC PHARMACEUTICALS, INC. (ORIC) had Class of Warrant or Right, Outstanding of 4.46 million shares as of 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Notes › Other Liabilities
us-gaap:ClassOfWarrantOrRightOutstanding · last filed 2026-08-03
- 2026-06-30: Class of Warrant or Right, Outstanding 4.46M shares.
- 2026-03-31: Class of Warrant or Right, Outstanding 4.46M shares.
- 2025-12-31: Class of Warrant or Right, Outstanding 4.46M shares.
- 2025-05-31: Class of Warrant or Right, Outstanding 5.10M shares.
| Period end | Class of Warrant or Right, Outstanding |
|---|---|
| 2026-06-30 | 4.46M shares 10-Q · filed 2026-08-03 |
| 2026-03-31 | 4.46M shares 10-Q · filed 2026-05-04 |
| 2025-12-31 | 4.46M shares 10-K · filed 2026-02-23 |
| 2025-05-31 | 5.10M shares 10-Q · filed 2026-08-03 |
| 2025-05-01 | 5.10M shares 10-K · filed 2026-02-23 |
| 2024-07-08 | 2.86M shares 10-K · filed 2025-02-18 |
| 2023-06-30 | 2.86M shares 10-K · filed 2025-02-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |